HC Wainwright Expects Reduced Earnings for UroGen Pharma

UroGen Pharma Ltd. (NASDAQ:URGN) – Stock analysts at HC Wainwright dropped their Q1 2025 EPS estimates for shares of UroGen Pharma in a note issued to investors on Tuesday, March 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.93) for the quarter, down from their prior estimate of ($0.83). HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for UroGen Pharma’s current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for UroGen Pharma’s Q2 2025 earnings at ($0.81) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.75) EPS, FY2025 earnings at ($3.27) EPS and FY2026 earnings at $0.29 EPS.

Several other research analysts also recently commented on URGN. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Monday. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, UroGen Pharma has a consensus rating of “Buy” and a consensus target price of $38.20.

UroGen Pharma Trading Up 0.7 %

NASDAQ:URGN opened at $10.90 on Thursday. The company’s 50 day moving average is $10.45 and its 200-day moving average is $11.69. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma has a 12 month low of $9.03 and a 12 month high of $20.70. The firm has a market cap of $255.65 million, a price-to-earnings ratio of -3.46 and a beta of 1.12.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The company had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million.

Institutional Investors Weigh In On UroGen Pharma

Large investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in UroGen Pharma by 4.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company’s stock valued at $231,000 after purchasing an additional 969 shares in the last quarter. Rhumbline Advisers raised its holdings in UroGen Pharma by 2.8% during the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock worth $546,000 after purchasing an additional 1,402 shares during the last quarter. MetLife Investment Management LLC boosted its stake in UroGen Pharma by 13.6% in the fourth quarter. MetLife Investment Management LLC now owns 22,766 shares of the company’s stock valued at $242,000 after acquiring an additional 2,727 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of UroGen Pharma by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company’s stock worth $996,000 after purchasing an additional 3,024 shares during the last quarter. Finally, Legal & General Group Plc grew its position in shares of UroGen Pharma by 24.6% during the 4th quarter. Legal & General Group Plc now owns 19,845 shares of the company’s stock worth $211,000 after buying an additional 3,920 shares during the period. 91.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling at UroGen Pharma

In related news, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now directly owns 145,666 shares of the company’s stock, valued at $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the transaction, the general counsel now directly owns 26,468 shares of the company’s stock, valued at $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.